Drug application
WEGOVY (SEMAGLUTIDE)
Drugs@FDA NDA 215256 · NOVO
Key facts
| Drug name | WEGOVY |
|---|---|
| Active ingredients | SEMAGLUTIDE |
| Application type | NDA |
| Application number | 215256 |
| Company | NOVO |
| Dosage forms | SOLUTION, SUBCUTANEOUS |
| Strength | 0.25MG/0.5ML (0.25MG/0.5ML) |
| Marketing status | Prescription |
| Reference listed drug | Yes |
| Latest submission class | Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated |
| Latest submission status date | Jun 4, 2021 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 10–99 Label versions
- 10–99 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: